Search results
Results from the WOW.Com Content Network
Novartis also initiated a program to assist patients who could not afford its version of the drug, concurrent with its product launch. [177] When examination of Novartis' patent application began in 2005, it came under immediate attack from oppositions initiated by generic companies that were already selling Gleevec in India and by advocacy ...
Novartis v. Union of India & Others is a landmark decision by a two-judge bench of the Indian Supreme Court on the issue of whether Novartis could patent Gleevec in India, and was the culmination of a seven-year-long litigation fought by Novartis. The Supreme Court upheld the Indian patent office's rejection of the patent application.
Bausch + Lomb was in a lawsuit with Novartis which claimed to have patents on a Bausch + Lomb product called PureVision. On June 26, 2002, a federal judge ruled that Bausch & Lomb did infringe on Ciba Vision (a subsidiary of Alcon) patents. [26] On July 2, 2004, the company announced that it had licensed the intellectual property of Novartis. [27]
Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it accidentally overpaid by nearly $210 ...
For premium support please call: 800-290-4726 more ways to reach us
Bayer, the company which bought Chiron Diagnostics, sued Chiron Corporation in 2002 citing that it hid patent and equipment problems from them during purchase negotiations. [32] The case filed in Delaware alleged breach of warranty, fraud, negligent misrepresentation, violation of the duty of good faith and fair dealing and breach of contract ...
Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q4 2024 Earnings Call Jan 31, 2025, 8:00 a.m. ET. Contents: Prepared Remarks. Questions and Answers. Call ...
Ciba was a chemical company based in and near Basel, Switzerland. "Ciba" stood for "Chemische Industrie Basel" (Chemical Industries Basel) and was formed when the non-pharmaceuticals elements of Novartis were spun out in 1997, [1] following the merger in the previous year of Ciba-Geigy and Sandoz that created Novartis.